TransMedics Group (NASDAQ:TMDX) Given “Hold” Rating at Needham & Company LLC

TransMedics Group (NASDAQ:TMDX)‘s stock had its “hold” rating reiterated by analysts at Needham & Company LLC in a note issued to investors on Wednesday,Benzinga reports.

A number of other brokerages have also commented on TMDX. JPMorgan Chase & Co. reissued a “neutral” rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Robert W. Baird lowered their price target on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Oppenheimer reaffirmed an “outperform” rating and set a $125.00 price objective on shares of TransMedics Group in a report on Tuesday, December 3rd. Piper Sandler lowered their target price on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $104.00 price target on shares of TransMedics Group in a research note on Tuesday, March 11th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average price target of $122.70.

TransMedics Group Price Performance

TransMedics Group stock opened at $70.79 on Wednesday. The business’s fifty day moving average is $68.43 and its two-hundred day moving average is $89.16. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20. The firm has a market cap of $2.38 billion, a P/E ratio of 75.31 and a beta of 2.12. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $177.37.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of TransMedics Group by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 3,635,919 shares of the company’s stock worth $226,700,000 after purchasing an additional 40,860 shares in the last quarter. FIL Ltd lifted its holdings in TransMedics Group by 28.0% during the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company’s stock worth $62,372,000 after acquiring an additional 218,961 shares in the last quarter. Braidwell LP acquired a new position in TransMedics Group in the fourth quarter valued at about $57,493,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of TransMedics Group by 16.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 903,086 shares of the company’s stock worth $56,307,000 after acquiring an additional 128,474 shares in the last quarter. Finally, Mackenzie Financial Corp increased its holdings in shares of TransMedics Group by 73.0% in the fourth quarter. Mackenzie Financial Corp now owns 828,147 shares of the company’s stock worth $51,635,000 after acquiring an additional 349,403 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.